Remove 2024 Remove Controlled Substances Remove FDA
article thumbnail

Is gabapentin a controlled substance?

The Checkup by Singlecare

Food and Drug Administration ( FDA ) for certain types of nerve pain, seizures, and restless leg syndrome. At this time, gabapentin isn’t recognized as a controlled substance on the federal level. However, several states have passed laws to classify it as a Schedule V controlled substance. In 2021, 70.9 pharmacies.

article thumbnail

It’s a Three-Peat: DEA and HHS Extend Telemedicine Flexibilities Until December 31, 2025

The FDA Law Blog

Palmer — In a Temporary Rule announced on November 19, 2024, DEA with input from HHS again extended current telemedicine flexibilities, which were first initiated on January 31, 2020 at the inception of the COVID-19 pandemic. By Karla L. The federal telemedicine flexibilities (i.e., The federal telemedicine flexibilities (i.e.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

More Diversion Cases and WCF’s Opioid & Fentanyl Abuse Management Summit

The FDA Law Blog

Houck — It seems as though we cannot get through a week without hearing about controlled substance diversion by employees at another hospital or healthcare facility. DEA, Palomar Hospital Pays $250,000 for Diverting Fentanyl ( June 3, 2024 ). By Larry K. Employee diversion can result in unwanted local and national publicity.

article thumbnail

DEA To Announce Hearing on Proposed Marijuana Rescheduling

The FDA Law Blog

The Drug Enforcement Administration (“DEA”) will announce Thursday in the Federal Register that it will hold a hearing on the proposed rescheduling of marijuana to schedule III at DEA Headquarters in Arlington, Virginia on December 2, 2024.

article thumbnail

FDA $7bn plans for 2024: disclose contract manufacturers, restart Cancer Moonshot

Pharmaceutical Technology

The US FDA has revealed its detailed budget proposal for FY2024, which would require pharma companies to name their active pharmaceutical ingredient (API) suppliers, restart President Biden’s Cancer Moonshot, inject cash into amyotrophic lateral sclerosis (ALS) research, and enforce stricter rules around manufacturing, recalls, and shortages.

FDA 59
article thumbnail

Joint Basis for FDA/HHS Marijuana Rescheduling Recommendation Unveiled

The FDA Law Blog

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. By Larry K. 53,688 (Aug. 53,767 (Aug. 21 U.S.C. §

FDA 67
article thumbnail

HP&M’s Larry Houck A Panelist in FDLI’s Marijuana Rescheduling Webinar

The FDA Law Blog

Last month the Department of Justice and the Drug Enforcement Administration submitted a notice of proposed rulemaking to reschedule cannabis from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. Hyman, Phelps & McNamara, P.C.